- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Obatoclax, Carboplatin/etoposide
- Drug
- Lead sponsor
- Gemin X
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 1,097
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Lymphoma, NHL, Non-Hodgkin Lymphoma
- Interventions
- AZD4877
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 3
- States / cities
- New York, New York • Philadelphia, Pennsylvania • Greenville, South Carolina
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Thiotepa, Carmustine, Autologous Stem Cell Transplant, Anthracycline-based induction chemotherapy
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
- Interventions
- PRT2527, Zanubrutinib, Venetoclax
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more
- Conditions
- MuSK Myasthenia Gravis
- Interventions
- MuSK-CAART
- Biological
- Lead sponsor
- Cabaletta Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Orange, California • Sacramento, California • Kansas City, Kansas + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- JCARH125, JCARH125 + anakinra
- Biological
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more
- Conditions
- Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
- Interventions
- CART-19
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- SB-485232, Rituximab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Indianapolis, Indiana
- Conditions
- Lymphoma
- Interventions
- CC-220, Rituximab, Obinutuzumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Lake Mary, Florida • Rochester, Minnesota + 3 more
- Conditions
- Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
- Interventions
- CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2030
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
- Interventions
- PF-08634404, Sigvotatug Vedotin, PF-08046054/SGN-PDL1V
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 55
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 29 more
- Conditions
- IPEX
- Interventions
- CD4^LVFOXP3
- Biological
- Lead sponsor
- Bacchetta, Rosa, MD
- Other
- Eligibility
- 4 Months to 35 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- IgG4 Related Disease, IgG4-RD
- Interventions
- elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
- Conditions
- Non-small Cell Lung Cancer, NSCLC
- Interventions
- Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 851 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Burbank, California • San Diego, California + 18 more
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- TAK-788, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 11
- States / cities
- Long Beach, California • Orange, California • Palo Alto, California + 6 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Docetaxel, Gemcitabine, Lurbinectedin (PM01183)
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 5
- States / cities
- Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Irvine, California • Long Beach, California + 13 more
- Conditions
- Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma
- Interventions
- Alisertib
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Duarte, California • Chapel Hills, North Carolina
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Rituximab, Bendamustine, MEDI-551
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Burbank, California • La Jolla, California + 11 more
- Conditions
- Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Stomatitis
- Interventions
- Ice, Normal Saline Solution
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Large B-cell Lymphoma
- Interventions
- NT-I7, CAR T-cell therapy
- Drug · Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lymphoma
- Interventions
- Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI), Allogeneic bone marrow transplantation, Cyclosporin (CSA), Mycophenolate mofetil (MMF), Methotrexate (MTX)
- Procedure · Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 19
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more